The study about thymopentin on reducing the infection rate in lymphoma after chemo-treatment

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-PRC-08000109

Enrollment

Unknown

Registered

2008-04-01

Start date

2008-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphoma

Interventions

control group:chemo-therapy

experimental group:chemo-therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who were certified NHL definitely with pathologic diagnosis and have no contraindication of chemo-treatment and thymopent

Exclusion criteria

Exclusion criteria: The patients who have contraindications of chemo-treatment and thymopent

Design outcomes

Primary

Measure	Time frame
White cell count;	—

Secondary

Measure	Time frame
Rate of infection;	—

Countries

China

Contacts

Public ContactShen Yongqi

215871582@qq.com+86 0 13215971475

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026